B-Cell Non-Hodgkin Lymphoma ' Pipeline Review, H2 2012

Find Industry reports, Company profiles
ReportLinker and Market Statistics
>> Get this Report Now by email!

B-Cell Non-Hodgkin Lymphoma ' Pipeline Review, H2 2012
Published on September 2012

Report Summary


Summary

Global Markets Direct's, 'B-Cell Non-Hodgkin Lymphoma - Pipeline Review, Global Markets Direct's, 'B-Cell Non-Hodgkin Lymphoma
- Pipeline Review, H2 2012', provides an overview of the indication's therapeutic pipeline. This report provides information on the
therapeutic development for B-Cell Non-Hodgkin Lymphoma, complete with latest updates, and special features on late-stage and
discontinued projects. It also reviews key players involved in the therapeutic development for B-Cell Non-Hodgkin Lymphoma. B-Cell
Non-Hodgkin Lymphoma - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's
proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from
company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated
disease.

Scope

- A snapshot of the global therapeutic scenario for B-Cell Non-Hodgkin Lymphoma.
- A review of the B-Cell Non-Hodgkin Lymphoma products under development by companies and universities/research institutes
based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the B-Cell Non-Hodgkin Lymphoma pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for B-Cell Non-Hodgkin Lymphoma.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive
advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding B-Cell Non-Hodgkin Lymphoma pipeline depth and focus of
Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to
enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

B-Cell Non-Hodgkin Lymphoma ' Pipeline Review, H2 2012 (From Slideshare) Page 1/9


Table of Content

Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
B-Cell Non-Hodgkin Lymphoma Overview 9
Therapeutics Development 10
An Overview of Pipeline Products for B-Cell Non-Hodgkin Lymphoma 10
B-Cell Non-Hodgkin Lymphoma Therapeutics under Development by Companies 12
B-Cell Non-Hodgkin Lymphoma Therapeutics under Investigation by Universities/Institutes 15
Late Stage Products 18
Comparative Analysis 18
Mid Clinical Stage Products 19
Early Clinical Stage Products 20
Discovery and Pre-Clinical Stage Products 21
B-Cell Non-Hodgkin Lymphoma Therapeutics ' Products under Development by Companies 22
B-Cell Non-Hodgkin Lymphoma Therapeutics ' Products under Investigation by Universities/Institutes 24
Companies Involved in B-Cell Non-Hodgkin Lymphoma Therapeutics Development 28
Bristol-Myers Squibb Company 28
Johnson & Johnson 29
Kyowa Hakko Kirin Co., Ltd. 30
Sanofi-Aventis 31
Genentech, Inc. 32
MedImmune LLC 33
Gilead Sciences, Inc. 34
Reliance Life Sciences Pvt. Ltd. 35
Millennium Pharmaceuticals, Inc. 36
Astellas Pharma Inc. 37
Biocon Limited 38
Cephalon, Inc. 39
SuperGen, Inc. 40
Merck KGaA 41
Celldex Therapeutics, Inc. 42
IMMUNOMEDICS, INC 43
Allos Therapeutics, Inc 44
Portola Pharmaceuticals, Inc. 45
Provenance Biopharmaceuticals Corp. 46
Synthon Pharmaceuticals, Inc. 47
Astellas Pharma GmbH 48
LFB Biotechnologies, S.A.S.U. 49



B-Cell Non-Hodgkin Lymphoma ' Therapeutics Assessment 50
Assessment by Monotherapy Products 50
Assessment by Combination Products 51
Assessment by Route of Administration 52
Assessment by Molecule Type 54
Drug Profiles 57
veltuzumab - Drug Profile 57
SAR-3419 - Drug Profile 59
moxetumomab pasudotox - Drug Profile 60
MDX-1203 - Drug Profile 61
CDX-1127 - Drug Profile 62
BVX-20 - Drug Profile 63
BLX-301 - Drug Profile 64
DI-Leu16-IL2 - Drug Profile 65
bendamustine hydrochloride - Drug Profile 66
pralatrexate - Drug Profile 68
siltuximab - Drug Profile 71
KW-2478 - Drug Profile 73
epratuzumab - Drug Profile 74
CpG 7909 + Rituxan - Drug Profile 75
Rituximab + Bendamustine + Lenalidomide - Drug Profile 76
PRT-2607 - Drug Profile 78
Bortezomib + Rituximab - Drug Profile 79
LBH589 + RAD001 - Drug Profile 80
ixabepilone - Drug Profile 82
Bendamustine + Rituximab - Drug Profile 84
Therapeutic allogeneic lymphocytes program - Drug Profile 85
Velcade + Rituximab - Drug Profile 86
GS 1101 + Bendamustine + Rituximab - Drug Profile 88
GS-1101 + Rituximab - Drug Profile 90
Revlimid + Dexamethasone + Rituximab - Drug Profile 92
Rituximab + Cyclophosphamide + Doxorubicin + Vincristine + Dexamethasone + Methotrexate + Cytarabine - Drug Profile 94
Velcade + Rituximab + Cyclophosphamide + Decadron - Drug Profile 96
Filgrastim + Rituximab + Carboplatin + Etoposide + Ifosfamide - Drug Profile 98
Filgrastim + Rituximab + Carboplatin + Etoposide + Ifosfamide - Drug Profile 100
G-CSF + Rituximab + Carmustine + Cisplatin + Cyclophosphamide + Etoposide + Peripheral Blood Stem Cell Transplantation +
Radiation Therapy - Drug Profile 102
Campath + Fludarabine + Cyclosporine + Mycophenolate Mofetil + Peripheral Stem Cell Transplantation - Drug Profile 105
Filgrastim + Rituximab + Cyclophosphamide + Cytarabine + Dexamethasone + Doxorubicin Hydrochloride + Etoposide + Ifosfamide +
Leucovorin + Methotrexate + Prednisone + Vincristine - Drug Profile 107
YM155 + Rituximab - Drug Profile 112
Rituximab + Cyclophosphamide + Vincristine + Prednisone + Doxorubicin - Drug Profile 113
RAD001 + Revlimid - Drug Profile 115
Cytoxan + Nipent + Rituxan - Drug Profile 116
R-CHOP + G3139 - Drug Profile 118
R-CHOP + G3139 - Drug Profile 120
Filgrastim + Rituximab + Carmustine + Cytarabine + Etoposide + Melphalan + IDEC Y2B8 + Peripheral Blood Stem Cell
Transplantation - Drug Profile 122



Rituximab + Methotrexate + Cytarabine + G-CSF + Radiation Therapy - Drug Profile 124
R-CODOX-M + Leucovorin + Filgrastim + Cytarabine - Drug Profile 125
R-CODOX-M + Leucovorin + Filgrastim + IVAC - Drug Profile 128
Filgrastim + Rituximab + Cyclophosphamide + Cytarabine + Leucovorin Calcium + Methotrexate + Prednisone + Therapeutic
hydrocortisone + Vincristine - Drug Profile 131
Cyclophosphamide + Vincristine + Prednisone + Doxorubicin - Drug Profile 134
Cyclophosphamide + Vincristine + Prednisone + Methotrexate - Drug Profile 136
Cyclophosphamide + Vincristine + Prednisone + Cytarabine - Drug Profile 138
Rituximab + Carboplatin + Etoposide + Ifosfamide + Vorinostat - Drug Profile 140
Rituximab + Vinorelbine - Drug Profile 142
rituximab - Drug Profile 144
Treanda + Ofatumumab - Drug Profile 145
ublituximab - Drug Profile 146
Rituximab + Hyper-CVAD + Pegfilgrastim + Cytarabine + Methotrexate - Drug Profile 148
Treanda + Carboplatin + Rituximab + Etoposide - Drug Profile 151
Rituximab + Etoposide + Cyclophosphamide + Doxorubicin + Vincristine + Prednisone + Filgrastim - Drug Profile 153
Treg Cells + CD3-Teff Cells + Fludarabine + Cyclophosphamide + Radiation Therapy + Umbilical Cord Blood Transplantation - Drug
Profile 156
binetrakin - Drug Profile 158
Milatuzumab + Veltuzumab - Drug Profile 160
Busulfan + Cyclophosphamide + Allogeneic Bone Marrow Transplantation + Methylprednisolone + Methotrexate + Cyclosporine -
Drug Profile 161
Lenalidomide + Rituximab + Carmustine + Etoposide + Cytarabine + Melphalan + Autologous Hematopoietic Stem Cell Transplant -
Drug Profile 163
Filgrastim + Cyclophosphamide + Cytarabine + Doxorubicin Hydrochloride + Etoposide + Ifosfamide + Leucovorin Calcium +
Methotrexate + Vincristine Sulfate - Drug Profile 166
Filgrastim + Cyclophosphamide + Cytarabine + Doxorubicin Hydrochloride + Etoposide + Ifosfamide + Leucovorin Calcium +
Methotrexate + Vincristine Sulfate - Drug Profile 169
Therapeutic tumor infiltrating lymphocytes program - Drug Profile 172
Therapeutic tumor infiltrating lymphocytes program - Drug Profile 174
Rituximab + Fenretinide - Drug Profile 176
Rituxan + Doxil - Drug Profile 177
Bendamustine + Etoposide + Cytosine Arabinoside + Melphalan - Drug Profile 178
Filgrastim + Pegfilgrastim + Rituximab + Cyclophosphamide + Cytarabine + Doxorubicin Hydrochloride + Etoposide + Ifosfamide +
Leucovorin Calcium + Liposomal Cytarabine + Methotrexate + Therapeutic Hydrocortisone + Vincristine Sulfate - Drug Profile 179
Carmustine + Etoposide + Cytarabine + Fludarabine Phosphate + Cyclophosphamide + Tacrolimus + Mycophenolate Mofetil +
Melphalan + Filgrastim + Stem Cell Transplantation + Radiation Therapy - Drug Profile 183
Pegfilgrastim + Rituximab - Drug Profile 186
Carmustine + Etoposide + Cytarabine + Fludarabine Phosphate + Cyclophosphamide + Cyclosporine + Mycophenolate Mofetil +
Melphalan + Therapeutic Autologous Lymphocytes + Stem Cell Transplantation + Radiation Therapy - Drug Profile 187
Rituximab + Carmustine + Cytarabine + Etoposide + Melphalan + Bortezomib + Vorinostat + Stem Cell Transplantation - Drug Profile
190
Fludarabine Phosphate + Total-Body Irradiation + Peripheral Blood Stem Cell Transplantation + Cyclosporine + Mycophenolate
Mofetil - Drug Profile 193
Prednisone + Vincristine + Cytarabine + Methotrexate + Etoposide + Cyclophosphamide + Doxorubicin - Drug Profile 195
Busulfan + Cyclophosphamide + Anti-Thymocyte Globulin + Methylprednisolone + Cyclosporine + Mycophenolate Mofetil + Allogeneic
Hematopoietic Stem Cell Transplantation + Umbilical Cord Blood Transplantation - Drug Profile 197
Rituximab + Cyclophosphamide + Doxorubicin + Prednisone + Vincristine - Drug Profile 200



G-CSF + Rituximab + Cyclophosphamide + Cytarabine + Leucovorin Calcium + Methotrexate + Prednisone + Therapeutic
Hydrocortisone + Vincristine - Drug Profile 202
Lenalidomide + Rituximab - Drug Profile 206
Fludarabine + Iodine I 131 Tositumomab + Stem Cell Transplantation - Drug Profile 207
Bortezomib + Rituximab - Drug Profile 209
Rituximab + Revlimid - Drug Profile 210
AT9283 + Docetaxel - Drug Profile 212
EMD-521873 - Drug Profile 213
RG-7593 - Drug Profile 215
Velcade + Temsirolimus - Drug Profile 216
DCDS-4501-A - Drug Profile 218
Rituximab + Cyclophosphamide + Prednisone + Dexamethasone + Vincristine + Methotrexate + Ifosphamide + Teniposide +
Etoposide + Cytarabine + Adriamycin + Vindesine - Drug Profile 219
PRT-2070 - Drug Profile 222
Bendamustine + Rituximab - Drug Profile 223
Bendamustine + Pentostatin + Ofatumumab - Drug Profile 224
panobinostat - Drug Profile 225
SAR245409 + Bendamustine + Rituximab - Drug Profile 226
SAR245409 + Bendamustine - Drug Profile 227
RG7593 + Rituxan - Drug Profile 228
CMC-544 + CCI-779 - Drug Profile 229
TP-0829 - Drug Profile 230
Rituximab Biosimilar + CHOP - Drug Profile 231
B-Cell Non-Hodgkin Lymphoma Therapeutics ' Drug Profile Updates 233
B-Cell Non-Hodgkin Lymphoma Therapeutics ' Discontinued Products 245
B-Cell Non-Hodgkin Lymphoma Therapeutics - Dormant Products 246
B-Cell Non-Hodgkin Lymphoma ' Product Development Milestones 247
Featured News & Press Releases 247
Appendix 256
Methodology 256
Coverage 256
Secondary Research 256
Primary Research 256
Expert Panel Validation 256
Contact Us 257
Disclaimer 257

List of Tables

Number of Products Under Development for B-Cell Non-Hodgkin Lymphoma, H2 2012 17
Products under Development for B-Cell Non-Hodgkin Lymphoma ' Comparative Analysis, H2 2012 18
Number of Products under Development by Companies, H2 2012 20
Number of Products under Development by Companies, H2 2012 (Contd..1) 21
Number of Products under Investigation by Universities/Institutes, H2 2012 23
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..1) 24
Comparative Analysis by Late Stage Development, H2 2012 25
Comparative Analysis by Mid Clinical Stage Development, H2 2012 26
Comparative Analysis by Early Clinical Stage Development, H2 2012 27



Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012 28
Products under Development by Companies, H2 2012 29
Products under Development by Companies, H2 2012 (Contd..1) 30
Products under Investigation by Universities/Institutes, H2 2012 31
Products under Investigation by Universities/Institutes, H2 2012 (Contd..1) 32
Bristol-Myers Squibb Company, H2 2012 35
Johnson & Johnson, H2 2012 36
Kyowa Hakko Kirin Co., Ltd., H2 2012 37
Sanofi-Aventis, H2 2012 38
Genentech, Inc., H2 2012 39
MedImmune LLC, H2 2012 40
Gilead Sciences, Inc., H2 2012 41
Reliance Life Sciences Pvt. Ltd., H2 2012 42
Millennium Pharmaceuticals, Inc., H2 2012 43
Astellas Pharma Inc., H2 2012 44
Biocon Limited, H2 2012 45
Cephalon, Inc., H2 2012 46
SuperGen, Inc., H2 2012 47
Merck KGaA, H2 2012 48
Celldex Therapeutics, Inc., H2 2012 49
IMMUNOMEDICS, INC, H2 2012 50
Allos Therapeutics, Inc, H2 2012 51
Portola Pharmaceuticals, Inc., H2 2012 52
Provenance Biopharmaceuticals Corp., H2 2012 53
Synthon Pharmaceuticals, Inc., H2 2012 54
Astellas Pharma GmbH, H2 2012 55
LFB Biotechnologies, S.A.S.U., H2 2012 56
Assessment by Monotherapy Products, H2 2012 57
Assessment by Combination Products, H2 2012 58
Assessment by Stage and Route of Administration, H2 2012 60
Assessment by Stage and Molecule Type, H2 2012 63
B-Cell Non-Hodgkin Lymphoma Therapeutics ' Drug Profile Updates 240
B-Cell Non-Hodgkin Lymphoma Therapeutics ' Discontinued Products 252
B-Cell Non-Hodgkin Lymphoma Therapeutics ' Dormant Products 253

List of Figures

Number of Products under Development for B-Cell Non-Hodgkin Lymphoma, H2 2012 17
Products under Development for B-Cell Non-Hodgkin Lymphoma ' Comparative Analysis, H2 2012 18
Products under Development by Companies, H2 2012 19
Products under Investigation by Universities/Institutes, H2 2012 22
Late Stage Products, H2 2012 25
Mid Clinical Stage Products, H2 2012 26
Early Clinical Stage Products, H2 2012 27
Discovery and Pre-Clinical Stage Products, H2 2012 28
Assessment by Monotherapy Products, H2 2012 57



Assessment by Combination Products, H2 2012 58
Assessment by Route of Administration, H2 2012 59
Assessment by Stage and Route of Administration, H2 2012 60
Assessment by Molecule Type, H2 2012 61
Assessment by Stage and Molecule Type, H2 2012 62


Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to:
Europe, Middle East and Africa : + 33 4 37 37 15 56
Asia, Oceania and America : + 1 (805) 617 17 93
If you have any questions please visit http://www.reportlinker.com/notify/contact

Order Information
Please verify that the product information is correct and select the format(s) you require.


Product Formats
Please select the product formats and the quantity you require.

1 User License--USD 2 500.00 Quantity: _____

Site License--USD 5 000.00 Quantity: _____

Corporate License--USD 7 500.00 Quantity: _____

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: Mr Mrs Dr Miss Ms Prof

First Name: _____________________________ Last Name: __________________________________

Email Address: __________________________________________________________________________

Job Title: __________________________________________________________________________

Organization: __________________________________________________________________________

Address: __________________________________________________________________________

City: __________________________________________________________________________

Postal / Zip Code: __________________________________________________________________________

Country: __________________________________________________________________________

Phone Number: __________________________________________________________________________

Fax Number: __________________________________________________________________________


Payment Information
Please indicate the payment method, you would like to use by selecting the appropriate box.

Payment by credit card Card Number: ______________________________________________

Expiry Date __________ / _________

CVV Number _____________________

Card Type (ex: Visa, Amex…) _________________________________

Payment by wire transfer Crédit Mutuel
RIB : 10278 07314 00020257701 89
BIC : CMCIFR2A
IBAN : FR76 1027 8073 1400 0202 5770 189

Payment by check UBIQUICK SAS
16 rue Grenette – 69002 LYON, FRANCE

Customer signature:

Please note that by ordering from Reportlinker you are agreeing to our Terms and Conditions at
http://www.reportlinker.com/index/terms

Please fax this form to:

Europe, Middle East and Africa : + 33 4 37 37 15 56

Asia, Oceania and America : + 1 (805) 617 17 93


B-Cell Non-Hodgkin Lymphoma ' Pipeline Review, H2 2012

Recommended

Recommended

More Related Content

More from ReportLinker.com

More from ReportLinker.com (20)

B-Cell Non-Hodgkin Lymphoma ' Pipeline Review, H2 2012